Interest of Medial Partial Arthrodesis in Degenerative and Inflammatory Damage of Lisfranc Tarsometatarsal Joint.

Arthritis Foot Clinical Trial

Official title:

Interest of Medial Partial Arthrodesis in Degenerative and Inflammatory Damage of Lisfranc Tarsometatarsal Joint.

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04937764
• Other study ID #: 2021PI033
• Status: Enrolling by invitation
• Start date: April 8, 2008
• Est. completion date: October 30, 2021

Study information

• Verified date: June 2021
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Research Hypothesis: Lisfranc tarsometatarsal joint arthrodesis is a reliable surgical procedure, allowing the restoration of satisfactory function and a painless foot with an acceptable complication rate.

Objective of the study: To analyze the clinical and radiographic results in the medium term of arthrodesis of the Lisfranc tarsometatarsal joint in cases of primary osteoarthritis, post-traumatic osteoarthritis or in cases of inflammatory pathology.

Description:

Data collection by return to the patient record:

• Clinical score

• Analysis of imagery (X-rays, CT scan, )

The patients included were those who had undergone arthrodesis of the medial Lisfranc joint

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 50
• Est. completion date: October 30, 2021
• Est. primary completion date: January 27, 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients who underwent Lisfranc arthrodesis for primary post-traumatic osteoarthritis or inflammatory disease between January 2008 and December 2020 in

• Age > 18 ans

Exclusion Criteria:

• Follow-up < 6 months

• Lost to follow-up

• lack of data in the patient record.

Related Conditions & MeSH terms

• Arthritis
• Arthritis Foot

Locations

Country	Name	City	State
France	CHRU NANCY, Central Hospital	Nancy	Meurthe Et Moselle

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical improvement of the AOFAS score of the midfoot	AOFAS Score	1 year post surgery